Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

References

• Szalontai K, Gémes N, Furák J, et al. Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer. J Clin Med. 2021;10(13):1. doi: 10.3390/jcm10132889.
   Web of Science ®Google Scholar
• Umeda A, Shimada H, Yamane T, et al. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. Front Physiol. 2023;14:1131949. doi: 10.3389/fphys.2023.1131949.
   PubMed Web of Science ®Google Scholar
• Terry PD, Dhand R. Inhalation therapy for stable COPD: 20 years of GOLD reports. Adv Ther. 2020;37(5):1812–9. doi: 10.1007/s12325-020-01289-y.
   PubMed Web of Science ®Google Scholar
• Venkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med. 2024;12(1):15–16. doi: 10.1016/S2213-2600(23)00461-7.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chuchalin A, Gor D, et al. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006;100(7):1152–1162. doi: 10.1016/j.rmed.2006.03.001.
   PubMed Web of Science ®Google Scholar
• Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102(4 Pt 2):S36–S51. doi: 10.1016/s0091-6749(98)70004-1.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Tarsilla M. Cochrane handbook for systematic reviews of interventions. J Multidiscip Eval. 2010;6(14):142–148. doi: 10.56645/jmde.v6i14.284.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Gu WJ, Wu XD, Wang F, et al. Ultrasound guidance facilitates radial artery catheterization: a meta-analysis with trial sequential analysis of randomized controlled trials. Chest. 2016;149(1):166–179. doi: 10.1378/chest.15-1784.
   PubMed Web of Science ®Google Scholar
• Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32(7):1320–1328. doi: 10.1016/j.clinthera.2010.06.022.
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584–594. doi: 10.1111/joim.12067.
   PubMed Web of Science ®Google Scholar
• Muiser S, Imkamp K, Seigers D, et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023;78(5):451–458. doi: 10.1136/thorax-2022-219620.
   PubMed Web of Science ®Google Scholar
• Wang MT, Lai JH, Huang YL, et al. Comparative effectiveness and safety of different types of inhaled long-acting β(2)-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β(2)-agonist plus inhaled corticosteroid fixed-dose combinations in COPD a propensity Score-Inverse probability of treatment weighting cohort study. Chest. 2021;160(4):1255–1270. doi: 10.1016/j.chest.2021.05.025.
   PubMed Web of Science ®Google Scholar
• Altaf M, Zubedi AM, Nazneen F, et al. Cost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India. Perspect Clin Res. 2015;6(3):150–158. doi: 10.4103/2229-3485.159940.
   PubMedGoogle Scholar
• Kalhan R, Slade D, Ray R, et al. Umeclidinium/vilanterol compared with fluticasone propionate/salmeterol, budesonide/formoterol, and tiotropium as initial maintenance therapy in patients with COPD who have high costs and comorbidities. Int J Chron Obstruct Pulmon Dis. 2021;16:1149–1161. doi: 10.2147/COPD.S298032.
   PubMed Web of Science ®Google Scholar
• Kern DM, Davis J, Williams SA, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015;16(1):52. doi: 10.1186/s12931-015-0210-x.
   PubMedGoogle Scholar
• Perrone V, Sangiorgi D, Buda S, et al. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. Int J Chron Obstruct Pulmon Dis. 2016;11:2749–2755. doi: 10.2147/COPD.S114554.
   PubMed Web of Science ®Google Scholar
• Roberts M, Mapel D, Petersen H, et al. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–776. doi: 10.3111/13696998.2011.622817.
   PubMedGoogle Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparing initial LABA-ICS inhalers in COPD: real-world effectiveness and safety. Respir Med. 2021;189:106645. doi: 10.1016/j.rmed.2021.106645.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi: 10.1164/ajrccm.157.5.9709032.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Donner CF. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs. 2000;60(2):307–320. doi: 10.2165/00003495-200060020-00005.
   PubMed Web of Science ®Google Scholar
• Celik G, Kayacan O, Beder S, et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration. 1999;66(5):434–439. doi: 10.1159/000029427.
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. doi: 10.1183/09031936.03.00031402.
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;18(2):CD002991.
   Google Scholar
• Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5(10):e009183. doi: 10.1136/bmjopen-2015-009183.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract. 2011;65(7):764–774. doi: 10.1111/j.1742-1241.2011.02685.x.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–565. doi: 10.2165/00003495-200969050-00004.
   PubMed Web of Science ®Google Scholar